Stifel analyst Thomas Shrader reiterated a Buy rating and $45 price target on Clovis Oncology (NASDAQ: CLVS) following data at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE